Clinical Updates
Alzheimer's
Disease
Arthritis
Asthma
Benign Prostatic Hypertrophy
Chronic
Lymphocytic Leukemia
Depression
Diabetes Mellitus
Dyspepsia
Erectile
Dysfunction
Fatty Liver
Gallstone
Hepatitis
Hypertension
Lung Cancer
Mesothelioma
Metabolic Syndrome
Obesity
Pneumonia
Prostate Cancer
Stroke
Sinusitis
Tinnitus
Medical Library
Breaking Medical News
Clinical Tools
Dermatology
Diabetes Corner
Evidence-Based Medicine
Free Medical Books
Free
Medical Journal
History Taking and Physical Examination
Medical Journal (popular)
Medical Notes
Medical Organizations
Palm Tools
Medical Physiology (Lecture)
Medical Resources
Medical Search
Online Clinical Calculator |
Effects of a fenofibrate/losartan
combination on the plasma concentration and urinary
excretion of purine bases
|
OBJECTIVE:
To assess the effects of a combination of fenofibrate and losartan on the
plasma concentrations and urinary excretion of purine bases in healthy male
subjects.
METHODS:
5 healthy males participated in a fenofibrate plus losartan combination
study. The plasma concentrations and urinary excretion of purine bases
(hypoxanthine, xanthine, uric acid) were measured before and after
administrations of losartan (100 mg o.d.) alone for 2 weeks, losartan and
fenofibrate together for 2 weeks and fenofibrate (300 mg o.d.) alone for 2
weeks, which were given consecutively over a 6-week period.
RESULTS:
Losartan alone significantly reduced the serum uric acid concentration and
increased uric acid excretion, whereas the combination of losartan and
fenofibrate reduced serum uric acid concentrations further with a
concomitant increased uric acid excretion. Fenofibrate alone also reduced
plasma uric acid concentration with an increase in urinary excretion,
although the effect was weak when compared with the combination treatment.
The plasma concentrations and urinary excretion of oxypurines remained
unchanged throughout the entire study.
CONCLUSION:
A combination of fenofibrate and losartan demonstrated an additive urate-lowering
effect which may be beneficial in the treatment of patients with gout and
hypertriglyceridemia.
Reference:
Int J Clin Pharmacol Ther. 2006 Jan;44(1):22-6. |
|